首页 > 最新文献

Journal of Interventional Medicine最新文献

英文 中文
Clinical efficacy of transjugular intrahepatic portosystemic shunt created through left or right branches of the portal vein: A meta-analysis 经左或右门静脉分支经颈静脉肝内门静脉系统分流术的临床疗效:荟萃分析
Q3 Medicine Pub Date : 2021-11-01 DOI: 10.1016/j.jimed.2021.08.002
Shaobo Zhai, Qi Cui, Fang Dong, Shiqi Wen, Moubo Si, Quan-jing Chen
{"title":"Clinical efficacy of transjugular intrahepatic portosystemic shunt created through left or right branches of the portal vein: A meta-analysis","authors":"Shaobo Zhai, Qi Cui, Fang Dong, Shiqi Wen, Moubo Si, Quan-jing Chen","doi":"10.1016/j.jimed.2021.08.002","DOIUrl":"https://doi.org/10.1016/j.jimed.2021.08.002","url":null,"abstract":"","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":"10 1","pages":"190 - 196"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75468084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research progress on circulating tumor cells of hepatocellular carcinoma 肝细胞癌循环肿瘤细胞的研究进展
Q3 Medicine Pub Date : 2021-11-01 DOI: 10.1016/j.jimed.2021.10.001
Chenyu Wan, Bing Zhou

Circulating tumor cells (CTCs) are the cells released from the primary tumor and found in the peripheral blood, which can colonize and develop at a distance through blood circulation. At present, the commonly used separation and detection methods of CTCs are mainly divided into physical methods, biological methods, and microfluidic chip-based methods. Monitoring CTC count and cell phenotype is of great significance for early screening and diagnosis of hepatocellular carcinoma (HCC). Moreover, the CTC count and cell phenotype are related to assessing the clinical efficacy of the treatment of HCC and the clinical stage of HCC patients. The CTCs count is also closely related to the overall survival, progression-free survival, and postoperative recurrence of patients with HCC.

循环肿瘤细胞(CTCs)是从原发性肿瘤中释放出来并在外周血中发现的细胞,可以通过血液循环在远处定植和发育。目前常用的CTC分离检测方法主要分为物理方法、生物方法和基于微流控芯片的方法。监测CTC计数和细胞表型对肝细胞癌(HCC)的早期筛查和诊断具有重要意义。此外,CTC计数和细胞表型与评估HCC治疗的临床疗效和HCC患者的临床分期有关。CTC计数也与HCC患者的总生存率、无进展生存率和术后复发密切相关。
{"title":"Research progress on circulating tumor cells of hepatocellular carcinoma","authors":"Chenyu Wan,&nbsp;Bing Zhou","doi":"10.1016/j.jimed.2021.10.001","DOIUrl":"https://doi.org/10.1016/j.jimed.2021.10.001","url":null,"abstract":"<div><p>Circulating tumor cells (CTCs) are the cells released from the primary tumor and found in the peripheral blood, which can colonize and develop at a distance through blood circulation. At present, the commonly used separation and detection methods of CTCs are mainly divided into physical methods, biological methods, and microfluidic chip-based methods. Monitoring CTC count and cell phenotype is of great significance for early screening and diagnosis of hepatocellular carcinoma (HCC). Moreover, the CTC count and cell phenotype are related to assessing the clinical efficacy of the treatment of HCC and the clinical stage of HCC patients. The CTCs count is also closely related to the overall survival, progression-free survival, and postoperative recurrence of patients with HCC.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":"4 4","pages":"Pages 181-183"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2096360221000533/pdfft?md5=be1e322a9b83292a1702ef89e0ddf074&pid=1-s2.0-S2096360221000533-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72099674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Research progress on circulating tumor cells of hepatocellular carcinoma 肝癌循环肿瘤细胞的研究进展
Q3 Medicine Pub Date : 2021-11-01 DOI: 10.1016/j.jimed.2021.10.001
Chen Wan, B. Zhou
{"title":"Research progress on circulating tumor cells of hepatocellular carcinoma","authors":"Chen Wan, B. Zhou","doi":"10.1016/j.jimed.2021.10.001","DOIUrl":"https://doi.org/10.1016/j.jimed.2021.10.001","url":null,"abstract":"","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":"109 1","pages":"181 - 183"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91334902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Endoleak management and postoperative surveillance following endovascular repair of internal carotid artery vascular diseases using Willis covered stent Willis覆膜支架血管内修复颈内动脉血管疾病后的内漏管理和术后监测
Q3 Medicine Pub Date : 2021-11-01 DOI: 10.1016/j.jimed.2021.09.001
Lin Ma, Shuo Yan, Hao Feng, Jichong Xu, Huaqiao Tan, Chun Fang

Background

To report the clinical results and experiences of endoleak management and postoperative surveillance following endovascular repair of internal carotid artery vascular diseases (ICAVDs) using Willis covered stents. METHODS: Seventy-three patients with ICAVD who received Willis covered stent implantation between November 2013 and September 2018 were retrospectively reviewed. The clinical data of endoleak management and postoperative surveillance were analyzed. RESULTS: Seventy-three cases with ICAVD, including 57 aneurysms, 11 carotid-cavernous sinus fistulas (CCF), and 5 surgical injuries, were all successfully installed with covered stents. Total isolation of ICAVDs was achieved in 59 patients (80.8%), and endoleaks were observed in 14 patients (19.2%). Of the 14 patients with endoleaks, 12 had type I endoleaks and 2 had type II; 13 had aneurysms and one had CCF. 10 patients with type I endoleaks received balloon dilatation, and 7 of them underwent a second stent-graft implantation after then. One patient with type II endoleak received embolization of the branch artery, and another one received follow-up observation. Endoleaks resolved in 6 patients and were minimal in 5 patients after balloon dilatation or the second stent implantation. During the follow-up period, minor endoleaks spontaneously resolved in 4 patients and minimal endoleaks were still demonstrated in 4 patients without enlargement of residual lumen and rupture. CONCLUSIONS: Endoleaks are the major complication after endovascular repair of ICAVDs and represent one of the limitations of this procedure. Improving the understanding and management of endoleaks can be beneficial in the clinical setting, including the popularization and application of this technique.

背景报告应用Willis覆膜支架血管内修复颈内动脉血管疾病(ICAVDs)后内漏管理和术后监测的临床结果和经验。方法:回顾性分析2013年11月至2018年9月期间接受Willis覆膜支架植入的73例ICAVD患者。分析内漏处理和术后监测的临床数据。结果:73例ICAVD患者,包括57个动脉瘤、11个颈动脉海绵窦瘘(CCF)和5个外科损伤,均成功安装了覆膜支架。59名患者(80.8%)完全分离出ICAVDs,14名患者(19.2%)观察到内漏。在14名内漏患者中,12名为I型内漏,2名为II型内漏;动脉瘤13例,CCF 1例。10名I型内漏患者接受了球囊扩张术,其中7人接受了第二次支架移植物植入术。一名II型内漏患者接受了分支动脉栓塞治疗,另一名患者接受了随访观察。球囊扩张或第二次支架植入后,6名患者的内漏消失,5名患者的外漏最小。在随访期间,4名患者的轻微内漏自发消退,4名病例的微小内漏仍然存在,没有残余管腔扩大和破裂。结论:内漏是血管内修复ICAVD后的主要并发症,也是该手术的局限性之一。提高对内漏的理解和管理在临床环境中是有益的,包括这项技术的推广和应用。
{"title":"Endoleak management and postoperative surveillance following endovascular repair of internal carotid artery vascular diseases using Willis covered stent","authors":"Lin Ma,&nbsp;Shuo Yan,&nbsp;Hao Feng,&nbsp;Jichong Xu,&nbsp;Huaqiao Tan,&nbsp;Chun Fang","doi":"10.1016/j.jimed.2021.09.001","DOIUrl":"https://doi.org/10.1016/j.jimed.2021.09.001","url":null,"abstract":"<div><h3>Background</h3><p>To report the clinical results and experiences of endoleak management and postoperative surveillance following endovascular repair of internal carotid artery vascular diseases (ICAVDs) using Willis covered stents. METHODS: Seventy-three patients with ICAVD who received Willis covered stent implantation between November 2013 and September 2018 were retrospectively reviewed. The clinical data of endoleak management and postoperative surveillance were analyzed. RESULTS: Seventy-three cases with ICAVD, including 57 aneurysms, 11 carotid-cavernous sinus fistulas (CCF), and 5 surgical injuries, were all successfully installed with covered stents. Total isolation of ICAVDs was achieved in 59 patients (80.8%), and endoleaks were observed in 14 patients (19.2%). Of the 14 patients with endoleaks, 12 had type I endoleaks and 2 had type II; 13 had aneurysms and one had CCF. 10 patients with type I endoleaks received balloon dilatation, and 7 of them underwent a second stent-graft implantation after then. One patient with type II endoleak received embolization of the branch artery, and another one received follow-up observation. Endoleaks resolved in 6 patients and were minimal in 5 patients after balloon dilatation or the second stent implantation. During the follow-up period, minor endoleaks spontaneously resolved in 4 patients and minimal endoleaks were still demonstrated in 4 patients without enlargement of residual lumen and rupture. CONCLUSIONS: Endoleaks are the major complication after endovascular repair of ICAVDs and represent one of the limitations of this procedure. Improving the understanding and management of endoleaks can be beneficial in the clinical setting, including the popularization and application of this technique.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":"4 4","pages":"Pages 212-218"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S209636022100051X/pdfft?md5=b44c405b74ea5867db1d118a36ef511b&pid=1-s2.0-S209636022100051X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72099534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical practice guidelines for the interventional treatment of advanced pancreatic cancer (5th edition) 晚期癌症介入治疗临床实践指南(第5版)
Q3 Medicine Pub Date : 2021-11-01 DOI: 10.1016/j.jimed.2021.08.001
Maoquan Li

Pancreatic cancer has become a major disease affecting people's health because of its insidiousness, rapid progression and poor prognosis. Based on the practical needs of clinical work, combined with domestic multi-center research and experience, this guideline provides constructive suggestions for the interventional treatment of pancreatic cancer.

癌症因其隐蔽性、进展快、预后差,已成为影响人们健康的主要疾病。本指南根据临床工作的实际需要,结合国内多中心的研究和经验,为癌症介入治疗提供建设性建议。
{"title":"Clinical practice guidelines for the interventional treatment of advanced pancreatic cancer (5th edition)","authors":"Maoquan Li","doi":"10.1016/j.jimed.2021.08.001","DOIUrl":"https://doi.org/10.1016/j.jimed.2021.08.001","url":null,"abstract":"<div><p>Pancreatic cancer has become a major disease affecting people's health because of its insidiousness, rapid progression and poor prognosis. Based on the practical needs of clinical work, combined with domestic multi-center research and experience, this guideline provides constructive suggestions for the interventional treatment of pancreatic cancer.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":"4 4","pages":"Pages 159-171"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jimed.2021.08.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72099673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Comparison of the postoperative pain change and spinal stenosis rate between percutaneous vertebroplasty combined with radiofrequency ablation and with 125I particle implantation in the treatment of metastatic spinal cord compression: A retrospective study 经皮椎体成形术联合射频消融和125I粒子植入治疗转移性脊髓压迫术后疼痛变化和椎管狭窄率的比较:一项回顾性研究
Q3 Medicine Pub Date : 2021-11-01 DOI: 10.1016/j.jimed.2021.10.002
Yu He , Shilong Han , Chungen Wu , Fei Ge , Jianbo Wang

Background context

Metastatic spinal cord compression (MSCC) seriously affects the survival rate.

Objective

The therapeutic effects of two treatment strategies for MSCC: percutaneous vertebroplasty (PVP) combined with radiofrequency ablation (RFA) and PVP combined with 125I particle implantation, were compared.

Study design

Retrospective study.

Patient sample

40 patients with MSCC were divided into two groups: 19 cases in the RFA group and 21 cases in the 125I group.

Method

All patients were accessed to determine the differences in pain, which was evaluated using the visual analog scale (VAS) at 1 week, 1 month, and 3 months after the operation, and spinal stenosis rates (SSRs), which were measured at 1 and 3 months after the operation, between the two groups.

Results

The VAS scores and SSRs at baseline were comparable between the RFA group and the 125I group (7.19 ​± ​2.07 vs 7.42 ​± ​1.95, 37.7% ​± ​11.2% vs 41.1% ​± ​11.4%). The VAS scores and SSRs at 1 month and 3 months after the operation were significantly reduced in both groups, compared with those at baseline. The VAS scores and SSRs in the 125I group were lower than those in the RFA group at 3 months after the operation (1.09 ​± ​0.97 vs 1.75 ​± ​1.06 p ​= ​0.048 and 12.3% ​± ​6.4% vs 18.1% ​± ​10.1% p ​= ​0.034), while the VAS scores at 1 week after the operation in the RFA group were lower than those in the 125I group (4.39 ​± ​1.34 vs 5.05 ​± ​1.82 p ​= ​0.049).

Conclusion

PVP combined with RFA has a slight advantage in relieving pain in the short term, while PVP combined with 125I particle implantation may have a better effect in the relieving pain and decreasing the SSRs at 3 months after the operation.

背景脊髓间充质干细胞压迫严重影响患者的生存率。目的比较经皮椎体成形术(PVP)联合射频消融(RFA)和PVP联合125I粒子植入治疗MSCC的疗效。研究设计回顾性研究。患者样本40例MSCC患者分为两组:RFA组19例,125I组21例。方法对所有患者进行访问,以确定两组患者在术后1周、1个月和3个月使用视觉模拟量表(VAS)评估的疼痛和术后1个月至3个月测量的椎管狭窄率(SSRs)的差异。结果RFA组和125I组在基线时的VAS评分和SSRs具有可比性(7.19​±​2.07对7.42​±​1.95,37.7%​±​11.2%对41.1%​±​11.4%)。两组在术后1个月和3个月的VAS评分和SSRs与基线时相比均显著降低。术后3个月,125I组的VAS评分和SSRs低于RFA组(1.09​±​0.97对1.75​±​1.06便士​=​0.048和12.3%​±​6.4%对18.1%​±​10.1%p​=​0.034),而RFA组术后1周VAS评分低于125I组(4.39​±​1.34对5.05​±​1.82便士​=​0.049)。结论PVP联合RFA在短期内有轻微的镇痛优势,而PVP联合125I粒子植入术在术后3个月可能有更好的镇痛和降低SSRs的效果。
{"title":"Comparison of the postoperative pain change and spinal stenosis rate between percutaneous vertebroplasty combined with radiofrequency ablation and with 125I particle implantation in the treatment of metastatic spinal cord compression: A retrospective study","authors":"Yu He ,&nbsp;Shilong Han ,&nbsp;Chungen Wu ,&nbsp;Fei Ge ,&nbsp;Jianbo Wang","doi":"10.1016/j.jimed.2021.10.002","DOIUrl":"https://doi.org/10.1016/j.jimed.2021.10.002","url":null,"abstract":"<div><h3>Background context</h3><p>Metastatic spinal cord compression (MSCC) seriously affects the survival rate.</p></div><div><h3>Objective</h3><p>The therapeutic effects of two treatment strategies for MSCC: percutaneous vertebroplasty (PVP) combined with radiofrequency ablation (RFA) and PVP combined with <sup>125</sup>I particle implantation, were compared.</p></div><div><h3>Study design</h3><p>Retrospective study.</p></div><div><h3>Patient sample</h3><p>40 patients with MSCC were divided into two groups: 19 cases in the RFA group and 21 cases in the <sup>125</sup>I group.</p></div><div><h3>Method</h3><p>All patients were accessed to determine the differences in pain, which was evaluated using the visual analog scale (VAS) at 1 week, 1 month, and 3 months after the operation, and spinal stenosis rates (SSRs), which were measured at 1 and 3 months after the operation, between the two groups.</p></div><div><h3>Results</h3><p>The VAS scores and SSRs at baseline were comparable between the RFA group and the <sup>125</sup>I group (7.19 ​± ​2.07 vs 7.42 ​± ​1.95, 37.7% ​± ​11.2% vs 41.1% ​± ​11.4%). The VAS scores and SSRs at 1 month and 3 months after the operation were significantly reduced in both groups, compared with those at baseline. The VAS scores and SSRs in the <sup>125</sup>I group were lower than those in the RFA group at 3 months after the operation (1.09 ​± ​0.97 vs 1.75 ​± ​1.06 p ​= ​0.048 and 12.3% ​± ​6.4% vs 18.1% ​± ​10.1% p ​= ​0.034), while the VAS scores at 1 week after the operation in the RFA group were lower than those in the <sup>125</sup>I group (4.39 ​± ​1.34 vs 5.05 ​± ​1.82 p ​= ​0.049).</p></div><div><h3>Conclusion</h3><p>PVP combined with RFA has a slight advantage in relieving pain in the short term, while PVP combined with <sup>125</sup>I particle implantation may have a better effect in the relieving pain and decreasing the SSRs at 3 months after the operation.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":"4 4","pages":"Pages 197-202"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2096360221000545/pdfft?md5=2af2df18278fcc667b2b8d1f19e33565&pid=1-s2.0-S2096360221000545-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72100064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Clinical efficacy of transjugular intrahepatic portosystemic shunt created through left or right branches of the portal vein: A meta-analysis 门静脉左右分支经颈静脉肝内门体分流术的临床疗效:荟萃分析
Q3 Medicine Pub Date : 2021-11-01 DOI: 10.1016/j.jimed.2021.08.002
Shaobo Zhai , Qi Cui , Fang Dong , Shiqi Wen , Moubo Si , Quan Chen

Background and aim

Transjugular intrahepatic portosystemic shunt (TIPS) is a technique successfully used to treat portal hypertension and its complications. However, the choice of the branch, left (L) or right (R), of the portal vein resulting in a better outcome is still under debate. Therefore, this meta-analysis aims to evaluate which branch has a better curative effect on patients treated with TIPS.

Methods

PubMed, EMBASE, Web of science, Cochrane Library databases, Wanfang database and CBM were used for our search in October 2019 and updated in June 2021. The following parameters were used in evaluation: overall mortality, hepatic encephalopathy, shunt dysfunction, variceal rebleeding and rate of postoperative ascites.

Results

There were seven studies included. The sample size was 1940. A lower risk of mortality was observed in TIPS-L-treated patients compared with TIPS-R-treated ones (OR ​= ​0.65, 95% CI ​= ​0.50–0.85, p ​= ​0.002). A lower risk of shunt dysfunction was observed in TIPS-L-treated patients compared with TIPS-R-treated ones (OR ​= ​0.53, 95% CI ​= ​0.33–0.87, p ​= ​0.01). And the TIPS-L group had a significantly higher hepatic encephalopathy-free rate than the TIPS-R group (OR ​= ​0.59, 95% CI ​= ​0.44–0.78, p ​= ​0.0002). However, the rate of rebleeding (OR ​= ​0.75, 95% CI ​= ​0.55–1.03, p ​= ​0.07) and incidence of postoperative ascites (OR ​= ​1.14, 95% CI ​= ​0.86–1.51, p ​= ​0.38) was not statistically significant between the two groups.

Conclusions

Based on the currently available evidence, the technique of TIPS through the left branch of the portal vein can significantly reduce the occurrence of overall postoperative mortality, hepatic encephalopathy and shunt dysfunction.

背景与目的经颈静脉肝内门体分流术(TIPS)是一种成功治疗门静脉高压及其并发症的技术。然而,门静脉左(L)或右(R)分支的选择是否能带来更好的结果仍在争论中。因此,本荟萃分析旨在评估哪一个分支对TIPS治疗的患者疗效更好。方法PubMed、EMBASE、Web of science、Cochrane Library数据库、万方数据库和CBM于2019年10月进行搜索,并于2021年6月更新。以下参数用于评估:总死亡率、肝性脑病、分流功能障碍、静脉曲张再出血和术后腹水率。结果共纳入7项研究。样本量为1940。与TIPS-R治疗的患者相比,TIPS-L治疗的患者死亡率较低(OR​=​0.65,95%CI​=​0.50–0.85,p​=​0.002)。与TIPS-R治疗的患者相比,TIPS-L治疗的患者出现分流功能障碍的风险较低(OR​=​0.53,95%CI​=​0.33–0.87,p​=​且TIPS-L组的肝性脑病无发病率明显高于TIPS-R组(OR​=​0.59,95%CI​=​0.44–0.78,p​=​0.0002)。然而,再出血率(OR​=​0.75,95%CI​=​0.55–1.03,p​=​0.07)和术后腹水发生率(OR​=​1.14,95%CI​=​0.86–1.51,p​=​0.38)在两组之间没有统计学意义。结论根据现有证据,经门静脉左支TIPS技术可显著降低术后总死亡率、肝性脑病和分流功能障碍的发生。
{"title":"Clinical efficacy of transjugular intrahepatic portosystemic shunt created through left or right branches of the portal vein: A meta-analysis","authors":"Shaobo Zhai ,&nbsp;Qi Cui ,&nbsp;Fang Dong ,&nbsp;Shiqi Wen ,&nbsp;Moubo Si ,&nbsp;Quan Chen","doi":"10.1016/j.jimed.2021.08.002","DOIUrl":"https://doi.org/10.1016/j.jimed.2021.08.002","url":null,"abstract":"<div><h3>Background and aim</h3><p>Transjugular intrahepatic portosystemic shunt (TIPS) is a technique successfully used to treat portal hypertension and its complications. However, the choice of the branch, left (L) or right (R), of the portal vein resulting in a better outcome is still under debate. Therefore, this meta-analysis aims to evaluate which branch has a better curative effect on patients treated with TIPS.</p></div><div><h3>Methods</h3><p>PubMed, EMBASE, Web of science, Cochrane Library databases, Wanfang database and CBM were used for our search in October 2019 and updated in June 2021. The following parameters were used in evaluation: overall mortality, hepatic encephalopathy, shunt dysfunction, variceal rebleeding and rate of postoperative ascites.</p></div><div><h3>Results</h3><p>There were seven studies included. The sample size was 1940. A lower risk of mortality was observed in TIPS-L-treated patients compared with TIPS-R-treated ones (OR ​= ​0.65, 95% CI ​= ​0.50–0.85, p ​= ​0.002). A lower risk of shunt dysfunction was observed in TIPS-L-treated patients compared with TIPS-R-treated ones (OR ​= ​0.53, 95% CI ​= ​0.33–0.87, p ​= ​0.01). And the TIPS-L group had a significantly higher hepatic encephalopathy-free rate than the TIPS-R group (OR ​= ​0.59, 95% CI ​= ​0.44–0.78, p ​= ​0.0002). However, the rate of rebleeding (OR ​= ​0.75, 95% CI ​= ​0.55–1.03, p ​= ​0.07) and incidence of postoperative ascites (OR ​= ​1.14, 95% CI ​= ​0.86–1.51, p ​= ​0.38) was not statistically significant between the two groups.</p></div><div><h3>Conclusions</h3><p>Based on the currently available evidence, the technique of TIPS through the left branch of the portal vein can significantly reduce the occurrence of overall postoperative mortality, hepatic encephalopathy and shunt dysfunction.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":"4 4","pages":"Pages 190-196"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2096360221000478/pdfft?md5=28359b6fce044912eb4be92a5eafa837&pid=1-s2.0-S2096360221000478-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72100065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of radiation doses between hepatic artery infusion chemotherapy and transarterial chemoembolization for liver cancer 癌症肝动脉灌注化疗与动脉栓塞化疗的放射剂量比较
Q3 Medicine Pub Date : 2021-11-01 DOI: 10.1016/j.jimed.2021.08.004
Hui Yuan , Hailei Lu , Jiahuan Zeng , Yan Zhang , Lujun Shen

Objective

To analyze the radiation dose received by patients during hepatic artery infusion chemotherapy (HAIC) and transarterial chemoembolization (TACE) procedures and the related influencing factors.

Methods

Data of 162 cases in the HAIC group and 230 cases in the TACE group were collected. The included covariates were Age (<45/45–59/≥60 years), BMI levels (underweight/normal weight/obesity), focus Dye of tumor (present/absent), lesion size (<5cm/≥5cm), superselection (present/absent), hepatic vascular variation (present/absent). The endpoints were postoperative dose-area product (DAP), exposure time and Air kerma (AK).

Results

Of all included patients, the HAIC group patients were younger than those in the TACE group (P ​= ​0.028). The proportion of patients with large lesions in the HAIC group was higher than the TACE group (45.7% vs. 33.9%, P ​= ​0.019). The proportion of patients who had superselection was lower in the HAIC group as compared to the TACE group (61.7% vs. 82.2%, P ​< ​0.001). Generally, the HAIC group has lower DAP, exposure time and AK by 36.3% (P ​< ​0.001), 38.2% (P ​< ​0.001), and 41.3% (P ​< ​0.001) than the TACE group, respectively. Linear regression analysis showed the procedure method (HAIC/TACE, P ​< ​0.001), type of DSA machine (Pheno/FD20, P ​< ​0.001), BMI levels (P ​< ​0.001), age (P ​= ​0.021), lesion size (<5cm/≥5 ​cm, P ​= ​0.031) significantly correlated with low DAP. In the HAIC group, the type of DSA machine and BMI correlated with the radiation dose, while in the TACE group, the type of DSA machine, BMI, and lesion size correlated with the radiation dose.

Conclusion

Compared with TACE, HAIC enables doctors and patients to receive lower radiation doses. Obese patients in both HAIC and TACE groups increase the radiation exposure in interventional doctors and patients, but large lesions only affect the radiation dose in the TACE procedure.

目的分析肝动脉灌注化疗(HAIC)和经动脉化疗栓塞(TACE)过程中患者的放射剂量及相关影响因素。方法收集HAIC组162例和TACE组230例的临床资料。纳入的协变量为年龄(<;45/45-59/≥60岁)、BMI水平(体重不足/正常体重/肥胖)、肿瘤病灶染料(存在/不存在)、病变大小(<:5cm/≥5cm)、超选择(存在/缺失)、肝血管变异(存在/无)。终点为术后剂量面积积(DAP)、暴露时间和空气kerma(AK)。结果HAIC组患者年龄明显小于TACE组(P​=​0.028)。HAIC组大面积病变的患者比例高于TACE组(45.7%对33.9%,P​=​与TACE组相比,HAIC组有超选择的患者比例较低(61.7%对82.2%,P​<;​HAIC组DAP、暴露时间和AK降低36.3%(P​<;​0.001)、38.2%(P​<;​0.001)和41.3%(P​<;​0.001)分别高于TACE组。线性回归分析显示程序方法(HAIC/TACE,P​<;​0.001),DSA机类型(Pheno/FD20,P​<;​0.001)、BMI水平(P​<;​0.001)、年龄(P​=​0.021),病变大小(<;5cm/≥5​cm,P​=​0.031)与低DAP显著相关。HAIC组的DSA机器类型和BMI与辐射剂量相关,而TACE组的DSA设备类型、BMI和病变大小与辐射剂量有关。结论与TACE相比,HAIC能使医生和患者接受较低的辐射剂量。HAIC和TACE组的肥胖患者增加了介入医生和患者的辐射暴露,但在TACE手术中,大的病变只影响辐射剂量。
{"title":"Comparison of radiation doses between hepatic artery infusion chemotherapy and transarterial chemoembolization for liver cancer","authors":"Hui Yuan ,&nbsp;Hailei Lu ,&nbsp;Jiahuan Zeng ,&nbsp;Yan Zhang ,&nbsp;Lujun Shen","doi":"10.1016/j.jimed.2021.08.004","DOIUrl":"https://doi.org/10.1016/j.jimed.2021.08.004","url":null,"abstract":"<div><h3>Objective</h3><p>To analyze the radiation dose received by patients during hepatic artery infusion chemotherapy (HAIC) and transarterial chemoembolization (TACE) procedures and the related influencing factors.</p></div><div><h3>Methods</h3><p>Data of 162 cases in the HAIC group and 230 cases in the TACE group were collected. The included covariates were Age (&lt;45/45–59/≥60 years), BMI levels (underweight/normal weight/obesity), focus Dye of tumor (present/absent), lesion size (&lt;5cm/≥5cm), superselection (present/absent), hepatic vascular variation (present/absent). The endpoints were postoperative dose-area product (DAP), exposure time and Air kerma (AK).</p></div><div><h3>Results</h3><p>Of all included patients, the HAIC group patients were younger than those in the TACE group (P ​= ​0.028). The proportion of patients with large lesions in the HAIC group was higher than the TACE group (45.7% vs. 33.9%, P ​= ​0.019). The proportion of patients who had superselection was lower in the HAIC group as compared to the TACE group (61.7% vs. 82.2%, P ​&lt; ​0.001). Generally, the HAIC group has lower DAP, exposure time and AK by 36.3% (P ​&lt; ​0.001), 38.2% (P ​&lt; ​0.001), and 41.3% (P ​&lt; ​0.001) than the TACE group, respectively. Linear regression analysis showed the procedure method (HAIC/TACE, P ​&lt; ​0.001), type of DSA machine (Pheno/FD20, P ​&lt; ​0.001), BMI levels (P ​&lt; ​0.001), age (P ​= ​0.021), lesion size (&lt;5cm/≥5 ​cm, P ​= ​0.031) significantly correlated with low DAP. In the HAIC group, the type of DSA machine and BMI correlated with the radiation dose, while in the TACE group, the type of DSA machine, BMI, and lesion size correlated with the radiation dose.</p></div><div><h3>Conclusion</h3><p>Compared with TACE, HAIC enables doctors and patients to receive lower radiation doses. Obese patients in both HAIC and TACE groups increase the radiation exposure in interventional doctors and patients, but large lesions only affect the radiation dose in the TACE procedure.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":"4 4","pages":"Pages 184-189"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jimed.2021.08.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72100066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Bronchial artery embolization for hemoptysis: A systematic review and meta-analysis 支气管动脉栓塞治疗咳血的系统评价和荟萃分析
Q3 Medicine Pub Date : 2021-11-01 DOI: 10.1016/j.jimed.2021.08.003
Zhiyuan Zheng , Zhiquan Zhuang , Minjie Yang , Jianjun Luo , Wen Zhang , Zhiping Yan , Xiaolin Wang

Objective

To assess the safety and efficacy of bronchial artery embolization (BAE) for hemoptysis.

Methods and materials

Databases with articles published in English, including Pubmed, Embase, Web of science and Chochrane library, were comprehensively searched to get accurate, up-to-date and sufficient literature about BAE for hemoptysis until March 2020. The technical success rates, immediate control rates, recurrence rates, mortality rates, and total complication rates (minor and major complication rates) extracted from the articles were pooled to estimate and assess the efficacy and safety of BAE using random-effect and fixed-effect models.

Results

21 articles published between 2008 and 2019, which include a total of 2511 patients, were studied to evaluate the safety and efficacy of BAE. The technical success and immediate control rates are 99.9% (95%CI: 99%–100%) and 99.5% (95%CI: 97.8%–99.2%), respectively. This study showed hemoptysis recurrence in 23.7% (95%CI: 18.5%–28.9%) with a mortality rate of 2% (95%CI: 0–3%). Additionally, the assessment of complications revealed a total complication rate of 13.4% (95% CI: 7.6–19.2%), in which 0.2% (95% CI: 0.2–0.4%) were major complications and 10% (95% CI: 4.7–9.6%) were minor complications.

Conclusion

BAE is an effective, safe, and feasible procedure with a low complication rate for hemoptysis patients. However, recurrence of hemoptysis is still at high risk after BAE due to different underlying diseases.

目的评价支气管动脉栓塞治疗咳血的安全性和有效性。方法和材料对Pubmed、Embase、Web of science和Chochrane图书馆等英文发表文章的数据库进行全面搜索,以获得准确、最新和充足的关于BAE治疗咳血的文献,直至2020年3月。将从文章中提取的技术成功率、即时控制率、复发率、死亡率和总并发症率(次要和主要并发症率)汇总起来,使用随机效应和固定效应模型评估BAE的疗效和安全性。结果研究了2008年至2019年间发表的21篇文章,共2511名患者,以评估BAE的安全性和有效性。技术成功率和即时控制率分别为99.9%(95%CI:99%-100%)和99.5%(95%CI:97.8%-99.2%)。本研究显示咳血复发率为23.7%(95%CI:18.5%-28.9%),死亡率为2%(95%CI:0-3%)。此外,并发症评估显示,总并发症发生率为13.4%(95%CI:7.6-19.2%),其中0.2%(95%CI:0.2-0.4%)为主要并发症,10%(95%CI:4.7-9.6%)为次要并发症。结论BAE是一种有效、安全、可行、并发症发生率低的治疗咳血的方法。然而,由于不同的潜在疾病,BAE后咳血复发的风险仍然很高。
{"title":"Bronchial artery embolization for hemoptysis: A systematic review and meta-analysis","authors":"Zhiyuan Zheng ,&nbsp;Zhiquan Zhuang ,&nbsp;Minjie Yang ,&nbsp;Jianjun Luo ,&nbsp;Wen Zhang ,&nbsp;Zhiping Yan ,&nbsp;Xiaolin Wang","doi":"10.1016/j.jimed.2021.08.003","DOIUrl":"https://doi.org/10.1016/j.jimed.2021.08.003","url":null,"abstract":"<div><h3>Objective</h3><p>To assess the safety and efficacy of bronchial artery embolization (BAE) for hemoptysis.</p></div><div><h3>Methods and materials</h3><p>Databases with articles published in English, including Pubmed, Embase, Web of science and Chochrane library, were comprehensively searched to get accurate, up-to-date and sufficient literature about BAE for hemoptysis until March 2020. The technical success rates, immediate control rates, recurrence rates, mortality rates, and total complication rates (minor and major complication rates) extracted from the articles were pooled to estimate and assess the efficacy and safety of BAE using random-effect and fixed-effect models.</p></div><div><h3>Results</h3><p>21 articles published between 2008 and 2019, which include a total of 2511 patients, were studied to evaluate the safety and efficacy of BAE. The technical success and immediate control rates are 99.9% (95%CI: 99%–100%) and 99.5% (95%CI: 97.8%–99.2%), respectively. This study showed hemoptysis recurrence in 23.7% (95%CI: 18.5%–28.9%) with a mortality rate of 2% (95%CI: 0–3%). Additionally, the assessment of complications revealed a total complication rate of 13.4% (95% CI: 7.6–19.2%), in which 0.2% (95% CI: 0.2–0.4%) were major complications and 10% (95% CI: 4.7–9.6%) were minor complications.</p></div><div><h3>Conclusion</h3><p>BAE is an effective, safe, and feasible procedure with a low complication rate for hemoptysis patients. However, recurrence of hemoptysis is still at high risk after BAE due to different underlying diseases.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":"4 4","pages":"Pages 172-180"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jimed.2021.08.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72100135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Endoleak management and postoperative surveillance following endovascular repair of internal carotid artery vascular diseases using Willis covered stent Willis覆膜支架在颈内动脉病变血管内修复术后的渗漏管理及术后监测
Q3 Medicine Pub Date : 2021-11-01 DOI: 10.1016/j.jimed.2021.09.001
Lin Ma, Shuo Yan, Hao Feng, Ji-chong Xu, Hua-qiao Tan, C. Fang
{"title":"Endoleak management and postoperative surveillance following endovascular repair of internal carotid artery vascular diseases using Willis covered stent","authors":"Lin Ma, Shuo Yan, Hao Feng, Ji-chong Xu, Hua-qiao Tan, C. Fang","doi":"10.1016/j.jimed.2021.09.001","DOIUrl":"https://doi.org/10.1016/j.jimed.2021.09.001","url":null,"abstract":"","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":"102 1","pages":"212 - 218"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82500072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Interventional Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1